Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gunagratinib in FGFR-altered bladder cancer
NCT04492293Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- May 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gunagratinib in bladder urothelial carcinoma (UC), sponsored by InnoCare Pharma. Started May 2020; status: recruiting.
02
Drugs
gunagratinib
03
Conditions
bladder urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04492293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492293.